The Nobel Prize in Physiology or Medicine 2016 was awarded for outstanding discoveries in the field of autophagy, which is a fundamental process for degrading and recycling cellular components. This groundbreaking research lead to the understanding of the central importance of autophagy in many physiological processes, such as in the adaptation to starvation or response to infection.
Major findings require not only outstanding minds but also excellent and reliable tools to create meaningful data. In a concerted effort to standardize research in this field, the autophagy community has established a set of guidelines for the use and interpretation of assays for monitoring autophagy .
PROGEN’s p62 antibodies enable the immunodetection of p62/SQSTM1 and are mentioned in these guidelines as useful reagents for monitoring autophagy by western blot (: p61, Fig. 15). The p62 protein plays an important role in ubiquitin-associated degradation and autophagy where it acts as a selective autophagy receptor, assembled in filamentous polymers and shuttling ubiquitinylated proteins to the autophagosomes .
Since 2000 when they were first sold by PROGEN, the p62 antibodies have been cited in numerous relevant papers on a wide range of scientific issues and are now recognized by researchers worldwide as dependable reagents for autophagy research.
PROGEN offers two anti-p62 guinea pig polyclonal sera that detect either N- or C-terminus of the p62 protein and that are both suitable for immunohistochemistry and western blots.
For more information on PROGEN’s p62 antibodies please visit:
anti-p62 / SQSTM1 (C-terminus) guinea pig polyclonal, serum
anti-p62 / SQSTM1 (N-terminus) guinea pig polyclonal, serum
PROGEN now offers its widely cited C-terminal p62/SQSTM1 antibody with a validated positive control for western blot analysis. The control is provided as lyophilized whole cell lysate from the PLC/PRF/5 human hepatoma cell line along with reference western blot data obtained with the p62/SQSTM1 C-terminal antibody.